V P Torchilin
Overview
Explore the profile of V P Torchilin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
194
Citations
4433
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Subhan M, Torchilin V
Nanomedicine
. 2020 Jun;
29:102239.
PMID: 32544449
Gene silencing by RNA interference represents a promising therapeutic approach. The development of carriers, e.g., polymers, lipids, peptides, antibodies, aptamers, small molecules, exosome and red blood cells, is crucial for...
2.
Subhan M, Torchilin V
Transl Res
. 2019 Aug;
214:62-91.
PMID: 31369717
Nanocarriers as drug delivery systems are promising and becoming popular, especially for cancer treatment. In addition to improving the pharmacokinetics of poorly soluble hydrophobic drugs by solubilizing them in a...
3.
Sarisozen C, Tan Y, Liu J, Bilir C, Shen L, Filipczak N, et al.
J Drug Target
. 2019 Jan;
27(5-6):624-633.
PMID: 30656973
p53, The tumour suppressor protein encoded by P53 gene, is the most commonly altered protein in the human malignancies. MDM2 controls the p53 activity through an autoregulatory feedback loop. p53...
4.
Sanchez-Purra M, Ramos V, Petrenko V, Torchilin V, Borros S
Int J Pharm
. 2016 Aug;
511(2):946-56.
PMID: 27498281
In order to treat metastasis in the brain, drug delivery systems must overcome multiple physical barriers between the point of administration and the target, such as the Blood-brain barrier, that...
5.
Kitatani K, Usui T, Sriraman S, Toyoshima M, Ishibashi M, Shigeta S, et al.
Oncogene
. 2015 Sep;
35(21):2801-12.
PMID: 26364609
Targeting cell motility, which is required for dissemination and metastasis, has therapeutic potential for ovarian cancer metastasis, and regulatory mechanisms of cell motility need to be uncovered for developing novel...
6.
Perche F, Biswas S, Wang T, Zhu L, Torchilin V
Angew Chem Int Ed Engl
. 2014 Feb;
53(13):3362-6.
PMID: 24554550
Altered vasculature and the resultant chaotic tumor blood flow lead to the appearance in fast-growing tumors of regions with gradients of oxygen tension and acute hypoxia (less than 1.4% oxygen)....
7.
Salzano G, Riehle R, Navarro G, Perche F, De Rosa G, Torchilin V
Cancer Lett
. 2013 Oct;
343(2):224-31.
PMID: 24099916
The discovery that survivin, a small anti-apoptotic protein, is involved in chemoresistance, opens a new scenario to overcome the drug resistance in cancer. It was shown that siRNA can efficiently...
8.
Kale A, Torchilin V
Polym Sci Ser A Chem Phys
. 2012 Nov;
51(6):730-737.
PMID: 23150741
Polyethylene glycol derivatives, such as block copolymers of polyethylene glycol and diacyllipids (for example, phosphatidylethanolamine) are widely used for surface modification of various pharmaceutical carriers in order to impart them...
9.
Khaw B, Torchilin V
Methods Mol Med
. 2011 Feb;
25:159-91.
PMID: 21318846
Targeting pharmaceuticals to the infarcted myocardium has two primary objectives: the diagnostic imaging of the infarcted myocardium and the delivery of therapeutic agents to compromised myocardial areas. Various diagnostic and...
10.
Musacchio T, Toniutti M, Kautz R, Torchilin V
Mol Pharm
. 2009 Sep;
6(6):1876-82.
PMID: 19737025
Cultured cancer cells undergoing apoptosis show an increase in the NMR signal at a chemical shift of 1.3 ppm (-CH2-) corresponding to the so-called "mobile lipids" (ML) originating from the...